News
AnHorn Medicines Achieves IND Clearance for AH-001 Protein Degrader Targeting Androgenetic Alopecia, First IND Milestone in 4 Years
Taipei, Taiwan — 7th November,
2024— AnHorn Medicines, an AI-accelerated platform company specializing in
protein degrader discovery, today announced that the U.S. Food and Drug
Administration (FDA) has granted Investigational New Drug (IND) clearance for
its novel protein degrader program. This IND marks a significant milestone for
the company, being its first regulatory achievement within just four years of
its inception. AnHorn Medicines is actively seeking collaboration opportunities
to expedite AH-001’s development for global availability.
AH-001, a novel, topically applied protein
degrader, is designed to selectively target and degrade the Androgen Receptor,
a known driver of several challenging dermatological and hair-loss disorders.
In preclinical studies, AH-001 demonstrated favorable safety profiles and
enhanced effectiveness compared to currently available therapies, positioning
it as a potentially transformative treatment option. Unlike traditional drugs,
AH-001 uses a targeted degradation approach to eliminate disease-causing
proteins, a mechanism that could offer greater durability and potency in
treating conditions related to AR overactivity.
“We are thrilled to achieve IND clearance
for AH-001, a milestone that exemplifies the speed and impact of our
AI-accelerated discovery platform, and our team’s exceptional capability and
commitment. The milestone brings us one step closer to delivering innovative
therapies for patients with limited options, and we’re excited to initiate our
clinical study to demonstrate the promise of our novel degrader technology.”
said Dr. Chu-Chiang Lin, Founder and CEO of AnHorn Medicines.
The clinical trial is scheduled to commence
in the fourth quarter of 2024, with trial sites planned in the United
States. The study will evaluate the safety and tolerability of AH-001. AnHorn
Medicines will continue to work closely with regulatory authorities and
potential partners to ensure efficient progress through clinical development.
About AnHorn Medicines
AnHorn Medicines is a biopharmaceutical company harnessing AI-accelerated
discovery to pioneer next-generation protein degrader therapeutics. Founded
with a commitment to redefine drug discovery, AnHorn Medicines leverages an
advanced AI platform to develop innovative therapies that target and degrade
disease-causing proteins, offering new hope to patients with unmet medical
needs.
Media Contact
Wendy Lin
Operations Mgr
anhorn01@anhornmed.com
+886-2-2786-2568
